Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2021 | $11.00 | Neutral → Buy | Citigroup |
| 9/28/2021 | Neutral → Buy | Citigroup | |
| 8/6/2021 | $13.00 → $6.00 | Sector Perform | RBC Capital |
| 8/6/2021 | $9.00 → $8.00 | Sell | Goldman Sachs |
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00
Citigroup upgraded Puma Biotechnology from Neutral to Buy
RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, June 1, 2025
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, April 1, 2025 a
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)